HEALTH TECHNOLOGY

Xandr to Partner with Lasso for Powering Omni-Channel Marketing Solutions for Healthcare and Pharma

Xandr | March 02, 2021

To simplify marketers’ ways of planning, activating, and measuring their Direct-to-Consumer (DTC) and Healthcare Provider (HCP) campaigns, Lasso and Xandr have just announced their strategic partnership. Lasso is well known as the first and only Omni channel platform for healthcare analytics and marketing.

Sale rep, patient touchpoints, a physician has been dramatically disrupted by the COVID-19 pandemic. This made the healthcare industry quickly adopt online resources, tools, and communication. To adapt to it, healthcare and pharmaceutical companies had to significantly increase their digital advertising budget.

They also have to make sure to return on this investment. For this, the company has to reach out to an audience measurably and cost-effectively. Lasso solves this by providing streamlining solutions for media planning, measurement, activation across social, programmatic, email, and connected TV.

Proprietary identity solution of Lasso and programmatic infrastructure Xandr have together made the new standard for HCP marketing.  On their target list, various healthcare marketers can match 99% of HCPs now. And, this would make the actively reach, through tailored messaging, an average of 80% of targets. Then, without any additional cost, physician-level reporting can be built into every HCP campaign daily.

Built-in measurement capabilities and advanced reporting make the marketers see the real-world impact campaigns in the platforms themselves without leaving. To script performance, Lasso correlates ad exposure and separates the net influence of operations by comparing unprotected populations to a pre-defined controller group. 

Lasso associates with the Xandr Invest DSP for its influential machine learning-based optimization tools, completely customizable API architecture, and straight connections to best media publishers and suppliers. This corporation highlights the constant variation of the spending through the Invest DSP platform, which produced 45% in the U.S. in 2020.

About Lasso

Lasso is well-known as the most comprehensive platform for healthcare analytics and marketing globally. In-house expertise and modern technology make Lasso provide effective one-stop solutions for marketers for seamless media planning, activation, and measurement. The company has offices in New York, NY, and Austin, Tx.

About Xandr

Xandr is a premium advertising platform for the global marketplace. The data-enabled technology platform of Xandr, including Xandr Monetize and Xandr Invest, enhances return on investment for both sellers and buyers.

 

 

Spotlight

CU sign: Anaesthesia - No Smoking. Doctor drawing fluid into syringe. Anesthesiologist / Anaesthetist applying anaesthesia. Several takes & MCU administering gases by face mask. Balloon pump. Patient under sheet on table - counting down and going under anaesthetic w/ nurse alongside. - shots repeated different angles & distances.

Spotlight

CU sign: Anaesthesia - No Smoking. Doctor drawing fluid into syringe. Anesthesiologist / Anaesthetist applying anaesthesia. Several takes & MCU administering gases by face mask. Balloon pump. Patient under sheet on table - counting down and going under anaesthetic w/ nurse alongside. - shots repeated different angles & distances.

Related News

HEALTH TECHNOLOGY

Olive Acquires Verata Health to Accelerate Artificial Intelligence Technology for Healthcare Industry

Olive | December 04, 2020

Prior approvals were the most expensive and tedious exchanges for suppliers in 2019 and are among the top reasons understanding consideration is deferred. As desperate clinics and wellbeing frameworks endeavor to meet patient, payer and supplier needs, the interest for AI innovations to build productivity and improve the patient experience has gotten basic. To help improve persistent admittance to mind and cure the $31 billion prior approval challenge, Olive reported the obtaining of Verata Health to tackle prior approvals for suppliers and payers through artificial intelligence as a joined arrangement under the Olive name. Verata is a main healthcare AI organization, empowering Frictionless Prior Authorization® for suppliers and payers. Flawlessly associated with the country's top electronic wellbeing record (EHR) frameworks, Verata's AI innovation naturally starts prior approvals, recovers payer rules, and recognizes and submit clinical documentation from the EHR. At the point when payers influence its AI stage, Verata empowers purpose of-care approvals for suppliers and patients, drastically quickening admittance to mind. Olive and Verata's joined prior approval arrangement smoothes out the cycle for suppliers, patients and payers by diminishing benefits by throughout 40% and cutting turnaround time for prior approvals by up to 80%. By coordinating Verata's answer, Olive can furnish clients with a genuine start to finish prior approval arrangement. The arrangement begins with deciding whether an approval is required, incorporates touchless accommodation of the prior approval demand, closes with robotizing denied guarantee requests and awards medical clinics a 360 degree perspective on their approval execution. This implies patients get the consideration they need quicker, yet in addition takes out befuddling charges patients get post-administration expressing their case has been denied by their protection. "Caring for patients at Mayo Clinic was life-changing," said Dr. Jeremy Friese, CEO of Verata and former Mayo physician executive. "We started Verata to have an impact on patients and providers across the country. Combining our AI solution with Olive's creates the leading platform to solve prior authorization on 'both ends of the fax machine' at providers and payers to drive impact for millions of patients." More than 60 Verata employees will join the Olive team following the acquisition, bringing Olive's total employee count to approximately 500. Olive's senior executive team will continue to grow as well: Lori Jones, Chief Revenue Officer, will retain her title and will also take on the role of President, Provider Market Dr. Jeremy Friese, Chief Executive Officer at Verata, will join Olive as President, Payer Market Dr. YiDing Yu, Chief Medical Officer at Verata, will become Olive's Chief Medical Officer "A broken healthcare system is one of the biggest challenges humanity faces today and prior authorization issues in particular are costing our nation billions of dollars. After partnering with Verata earlier this year, we saw incredible potential for Verata's technology to reduce the amount of time and money spent on prior authorizations, and to eliminate delays in patient care," said Sean Lane, CEO of Olive. "This acquisition allows Olive to accelerate innovation in areas where we can drive the biggest impact, and further expands our solutions to providers and payers seeking to transform healthcare." The procurement follows Olive's ongoing $225.5 million financing round to reinforce the organization's R&D stash and drive the development of Olive's AI labor force for suppliers and payers. As of late, Olive additionally reported Olive Helps: another AI stage that conveys focused on data to healthcare laborers to empower better, quicker outcomes while lessening the time spent on managerial errands. With Olive's ongoing energy, Verata's set-up of AI devices will extend Olive's effect as it mechanizes the $31 billion issue of prior approvals in healthcare. About Olive Olive's AI workforce is built to fix our broken healthcare system by addressing healthcare's most burdensome issues -- delivering hospitals and health systems and payers increased revenue, reduced costs, and increased capacity. People feel lost in the system today and healthcare employees are essentially working in the dark due to outdated technology that creates a lack of shared knowledge and siloed data. Olive is designed to drive connections, shining a new light on the broken healthcare processes that stand between providers delivering patient care and payers. She uses AI to reveal life-changing insights that make healthcare more efficient, affordable and effective. Olive's vision is to unleash a trillion dollars of hidden potential within healthcare by connecting its disconnected systems. Olive is improving healthcare operations today, so everyone can benefit from a healthier industry tomorrow. About Verata Health Verata Health empowers hospitals, health systems and payers to take control of one of the biggest and most challenging problems in healthcare — prior authorization. A physician-led company trusted by customers across the country, Verata's artificial intelligence platform is obsoleting the fax machine with Frictionless Prior Authorization®. Supporting both simple and clinically complex prior authorizations, Verata Health helps both providers and payers increase revenue, reduce administrative burden and accelerate patient access. Verata Health's investors include BlueCross BlueShield Venture Partners, LRVHealth, CapitalFour, 3M and Bessemer Venture Partners. TripleTree, LLC served as the exclusive financial advisor to Verata Health for this transaction.

Read More

HEALTH TECHNOLOGY

Novarad Releases Web Version of Its Medical Image Sharing System, CyrptoChartTM

Novarad Corporation | June 02, 2022

The Industry leader in medical imaging technologies, Novorad, announced the release of a web-only version of CryptoChartTM, a cutting-edge medical imaging system that offers secure storage and transfer of digital health records through encrypted QR and web access codes. The Lite version of CryptoChartTM will be available at no extra cost, empowering patients and their providers with a seamless experience. Transparent and complete access to medical imaging technology. This will also eliminate accessibility concerns regardless of the geographical setting. "One of the recurring frustrations by providers and patients alike is sharing information from different facilities while maintaining strict privacy. Being able to send large digital files like medical images quickly with a built-in viewer anywhere in the world helps simplify access, improve patient outcomes, and lower the cost of providing world-class care anywhere." David GrandPre, Sr. Director of Product, Novarad CryptoChartTM Lite instantly addresses the challenge of isolated systems and delivers a streamlined access to medical reports and imaging without the use of portals or login information. The information, URL, and passwords are embedded into an ultra-secure, optically readable, and shareable QR code. "The CryptoChart Lite service is exactly the prescription needed for healthcare professionals frustrated by the barriers of accessing medical images. It's like a medical Dropbox. Technology should make it easier to provide patient care, not get in our way. The Lite version allows facilities globally to try out the CryptoChart platform. We've made it easy with no sign-up required. Just drag and drop the file." Dr. Wendell Gibby, Founder and CEO, Novarad

Read More

AI

HALO Diagnostics Launches Subtle Medical's Suite of AI-powered Imaging Technologies for Better Patient Care

Subtle Medical | October 06, 2021

HALO Diagnostics (formerly Desert Medical Imaging), a leading medical imaging provider headquartered in Southern California, announced today a partnership with Subtle Medical, a healthcare technology company focused on AI-powered software solutions that enable faster, safer, and smarter medical imaging. HALO has implemented both SubtleMR™ and SubtlePET™ image enhancement software at multiple locations, leading to higher quality imaging and improved patient experience. "With Subtle's technology, we now have the ability to restore image quality to standard of care when conducting shorter scan times for MRI and PET and lower dose PET exams. This combination allows us to better tailor scans to patient needs and improve workflow efficiency, patient experience, and patient safety. The addition of Subtle Medical's technology to HALO Diagnostics furthers our commitment to precision focused, personalized healthcare." MD, Chief Medical Officer at HALO Diagnostics HALO Diagnostics is focused on saving and extending the quality of people's lives through the early detection of the leading causes of death with precision diagnostics. Combining leaders from the medical, scientific and high technology communities, HALO Diagnostics is a leader in the early detection of cancer's like Prostate and Breast in men and women. "We could not be more pleased that Halo Diagnostics has adopted both SubtleMR and SubtlePET. Our unique technology not only supports a better patient experience from less time in the imaging suite, but also increased perceived safety. We look forward to a long partnership with Halo". Chief Commercial Officer for Subtle Medical Subtle Medical has an extensive product pipeline. The company's technologies utilize proprietary deep learning algorithms that integrate seamlessly with any OEM scanner to improve image quality from accelerated image acquisition without any alteration in the imaging specialists' workflow. About HALO HALO Diagnostics (HALO Dx, Inc.) changes patient lives and outcomes through early detection of the leading causes of death with precision diagnostics. We accomplish this with a personalized diagnostic ensemble including advanced imaging, genomics, non-invasive liquid biomarkers, and community-based data at scale combined with deep learning algorithms. By optimizing all these solutions under the HALO Diagnostics platform, we provide rapid, precise, actionable results to enable life-changing treatments by physicians for their patients. About Subtle Medical Subtle Medical, Inc. is an innovative healthcare technology company with a suite of software solutions that use deep learning to increase the quality and efficiency of medical imaging. Subtle's software solutions are integrated at hospitals and imaging institutions worldwide. It was named a CB Insights Top AI 100 and Digital Health 150 company in 2020 and is an Nvidia Inception Award Winner.

Read More